Ardelyx, Inc. has entered into a Commercial Supply Agreement with Catalent Pharma Solutions for the manufacturing of IBSRELA, effective July 23, 2024, with a minimum batch purchase commitment and annual price adjustments based on the producer price index, lasting until December 31, 2028.